Decreased Risk of Renal Allograft Thrombosis Associated With Interleukin-2 Receptor Antagonists: A Report of the NAPRTCS
03/2006
Journal Article
Authors:
Smith, J.;
Stablein, D.;
Singh, A.;
Harmon, W.;
McDonald, R.
Secondary:
Am J Transplant
Volume:
6
Pagination:
585-588
URL:
http://www.ncbi.nlm.nih.gov/pubmed/16468970
Keywords:
Adolescent; Antibodies- Monoclonal; Canada; Child; Costa Rica; Female; Follow-Up Studies; Immunosuppressive Agents; Incidence; Infant; kidney transplantation; Male; Mexico; Receptors- Interleukin-2; Renal Artery Obstruction; Thrombosis
Abstract:
{Graft thrombosis is the most common cause of first year graft failure in pediatric renal transplantation. The North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) database was analyzed for cases of graft failure due to thrombosis among patients transplanted from 1998 to 2004. The impact of interleukin-2 (IL-2) receptor antagonists as induction therapy was determined. There were a total of 51 graft failures due to thrombosis among the 2750 reported renal transplants (1.85%) (95% CI (1.39%, 2.41%)). This represents the most common cause of graft loss during the first year post-transplant accounting for 35% of first year losses and 18% of all graft losses. The incidence of thrombosis among patients who received IL-2 receptor antibodies was 1.07% (12/1126) compared to 2.40% (39/1624) among patients who did not (OR 0.44, 95% CI 0.23, 0.84
